Rhythm Pharmaceuticals
RYTM
91 hedge funds and large institutions have $920M invested in Rhythm Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 38 increasing their positions, 18 reducing their positions, and 10 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 18
110% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 10
48% more capital invested
Capital invested by funds: $621M → $920M (+$298M)
14% more funds holding
Funds holding: 80 → 91 (+11)
0.91% more ownership
Funds ownership: 92.62% → 93.53% (+0.91%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
+$5.88M |
| 2 |
BlackRock
New York
|
+$5.82M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.07M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$4.09M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$10.9M |
| 2 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$8.77M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.14M |
| 4 |
PA
Perceptive Advisors
New York
|
-$2.6M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.39M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -121 | Closed |
|
RYTM Hedge Fund Activity: Q2 2020 in Review
91 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q2 2020, worth a combined $920M — up 48% from $621M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RYTM positions and 10 closed out — a net gain of 11 holders — while 38 added to existing stakes and 18 trimmed.
The largest buyer was Marshall Wace North America, opening a new position worth an estimated $5.88M. The largest seller was Deerfield Management, cutting an estimated $10.9M.
- 91 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q2 2020, up from 80 in Q1 2020.
- Funds reported $920M of Rhythm Pharmaceuticals stock for Q2 2020, up 48% quarter-over-quarter.
- 21 funds opened new Rhythm Pharmaceuticals positions in Q2 2020 and 10 closed out, a net change of +11 holders.
- The largest Rhythm Pharmaceuticals buyer in Q2 2020 was Marshall Wace North America, an estimated $5.88M added.
- The largest Rhythm Pharmaceuticals seller in Q2 2020 was Deerfield Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q2 2020.